Effect of 3-bromopyruvate and atovaquone on infection during in vitro interaction of Toxoplasma gondii and LLC-MK2 cells.
de Lima, Loyze Paola O; Seabra, Sergio H; Carneiro, Henrique; Barbosa, Helene S.
Antimicrob Agents Chemother
; 59(9): 5239-49, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26077255
Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.
Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review.
Development of an in vitro system to study the developmental stages of Toxoplasma gondii using a genetically modified strain expressing markers for tachyzoites and bradyzoites.
Within-host selection of drug resistance in a mouse model of repeated interrupted treatment of Plasmodium yoelii infection.
In Vitro Analysis of the Interaction between Atovaquone and Proguanil against Liver Stage Malaria Parasites.
Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil.
New naphthoquinones and an alkaloid with in vitro activity against Toxoplasma gondii RH and EGS strains.
Guanabenz repurposed as an antiparasitic with activity against acute and latent toxoplasmosis.
Screening of compound libraries for inhibitors of Toxoplasma growth and invasion.
Nanoparticles show potential to retard bradyzoites in vitro formation of Toxoplasma gondii.